International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease
Purpose Positron emission tomography (PET) with the first and only tau targeting radiotracer of 18 F-flortaucipir approved by FDA has been increasingly used in depicting tau pathology deposition and distribution in patients with cognitive impairment. The goal of this international consensus is to he...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2022-02, Vol.49 (3), p.895-904 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 904 |
|---|---|
| container_issue | 3 |
| container_start_page | 895 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 49 |
| creator | Tian, Mei Civelek, A. Cahid Carrio, Ignasi Watanabe, Yasuyoshi Kang, Keon Wook Murakami, Koji Garibotto, Valentina Prior, John O. Barthel, Henryk Zhou, Rui Hou, Haifeng Dou, Xiaofeng Jin, Chentao Zuo, Chuantao Zhang, Hong |
| description | Purpose
Positron emission tomography (PET) with the first and only tau targeting radiotracer of
18
F-flortaucipir approved by FDA has been increasingly used in depicting tau pathology deposition and distribution in patients with cognitive impairment. The goal of this international consensus is to help nuclear medicine practitioners procedurally perform
18
F-flortaucipir PET imaging.
Method
A multidisciplinary task group formed by experts from various countries discussed and approved the consensus for
18
F-flortaucipir PET imaging in Alzheimer’s disease (AD), focusing on clinical scenarios, patient preparation, and administered activities, as well as image acquisition, processing, interpretation, and reporting.
Conclusion
This international consensus and practice guideline will help to promote the standardized use of
18
F-flortaucipir PET in patients with AD. It will become an international standard for this purpose in clinical practice. |
| doi_str_mv | 10.1007/s00259-021-05673-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8803772</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2624034554</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-5328f17ff7e4ed3cc2e21b09e24e00ec83c68d50f51724daab914c028cb5e2cf3</originalsourceid><addsrcrecordid>eNp9kcFqFTEUhoMotlZfwFXAjZvRk2QyyWyEUlotFHTRrkNu5mRuytzkmsxY6srX8PV8EnO9pdIuujoHzvf__JyfkLcMPjAA9bEAcNk3wFkDslOiuXlGDlnH-kaB7p_f7woOyKtSrgGY5rp_SQ5E2yste3lI8DzOmKOdQ4p2oi7FgrEshaZI5zXSpSBNns52od9OL2nY2DHEkdoR40yZPmv8lHK9urANmYZIj6efawwbzH9-_S50CAVtwdfkhbdTwTd384hcnZ1ennxpLr5-Pj85vmic0GxupODaM-W9whYH4RxHzlbQI28RAJ0WrtODBC-Z4u1g7apnrQOu3Uoid14ckU973-2y2uDgashsJ7PNNXe-NckG8_ASw9qM6YfRGoRSvBq8vzPI6fuCZTabUBxOk42YlmJ4xzquFcgd-u4Rep2W-slpR_EWRCtlWym-p1xOpWT092EYmF2LZt-iqS2afy2amyoSe1GpcBwx_7d-QvUXfyahDg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2624034554</pqid></control><display><type>article</type><title>International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease</title><source>SpringerLink Journals - AutoHoldings</source><creator>Tian, Mei ; Civelek, A. Cahid ; Carrio, Ignasi ; Watanabe, Yasuyoshi ; Kang, Keon Wook ; Murakami, Koji ; Garibotto, Valentina ; Prior, John O. ; Barthel, Henryk ; Zhou, Rui ; Hou, Haifeng ; Dou, Xiaofeng ; Jin, Chentao ; Zuo, Chuantao ; Zhang, Hong</creator><creatorcontrib>Tian, Mei ; Civelek, A. Cahid ; Carrio, Ignasi ; Watanabe, Yasuyoshi ; Kang, Keon Wook ; Murakami, Koji ; Garibotto, Valentina ; Prior, John O. ; Barthel, Henryk ; Zhou, Rui ; Hou, Haifeng ; Dou, Xiaofeng ; Jin, Chentao ; Zuo, Chuantao ; Zhang, Hong ; Molecular Imaging-based Precision Medicine Task Group of A3 (China-Japan-Korea) Foresight Program</creatorcontrib><description>Purpose
Positron emission tomography (PET) with the first and only tau targeting radiotracer of
18
F-flortaucipir approved by FDA has been increasingly used in depicting tau pathology deposition and distribution in patients with cognitive impairment. The goal of this international consensus is to help nuclear medicine practitioners procedurally perform
18
F-flortaucipir PET imaging.
Method
A multidisciplinary task group formed by experts from various countries discussed and approved the consensus for
18
F-flortaucipir PET imaging in Alzheimer’s disease (AD), focusing on clinical scenarios, patient preparation, and administered activities, as well as image acquisition, processing, interpretation, and reporting.
Conclusion
This international consensus and practice guideline will help to promote the standardized use of
18
F-flortaucipir PET in patients with AD. It will become an international standard for this purpose in clinical practice.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-021-05673-w</identifier><identifier>PMID: 34978595</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Alzheimer's disease ; Cardiology ; Cognitive ability ; Fluorine isotopes ; Guidelines ; Image acquisition ; Imaging ; Medical imaging ; Medicine ; Medicine & Public Health ; Neurodegenerative diseases ; Neurology ; Nuclear Medicine ; Oncology ; Orthopedics ; Patients ; Positron emission ; Positron emission tomography ; Radioactive tracers ; Radiology ; Tau protein ; Tomography</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2022-02, Vol.49 (3), p.895-904</ispartof><rights>The Author(s) 2022</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-5328f17ff7e4ed3cc2e21b09e24e00ec83c68d50f51724daab914c028cb5e2cf3</citedby><cites>FETCH-LOGICAL-c381t-5328f17ff7e4ed3cc2e21b09e24e00ec83c68d50f51724daab914c028cb5e2cf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00259-021-05673-w$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00259-021-05673-w$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids></links><search><creatorcontrib>Tian, Mei</creatorcontrib><creatorcontrib>Civelek, A. Cahid</creatorcontrib><creatorcontrib>Carrio, Ignasi</creatorcontrib><creatorcontrib>Watanabe, Yasuyoshi</creatorcontrib><creatorcontrib>Kang, Keon Wook</creatorcontrib><creatorcontrib>Murakami, Koji</creatorcontrib><creatorcontrib>Garibotto, Valentina</creatorcontrib><creatorcontrib>Prior, John O.</creatorcontrib><creatorcontrib>Barthel, Henryk</creatorcontrib><creatorcontrib>Zhou, Rui</creatorcontrib><creatorcontrib>Hou, Haifeng</creatorcontrib><creatorcontrib>Dou, Xiaofeng</creatorcontrib><creatorcontrib>Jin, Chentao</creatorcontrib><creatorcontrib>Zuo, Chuantao</creatorcontrib><creatorcontrib>Zhang, Hong</creatorcontrib><creatorcontrib>Molecular Imaging-based Precision Medicine Task Group of A3 (China-Japan-Korea) Foresight Program</creatorcontrib><title>International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Purpose
Positron emission tomography (PET) with the first and only tau targeting radiotracer of
18
F-flortaucipir approved by FDA has been increasingly used in depicting tau pathology deposition and distribution in patients with cognitive impairment. The goal of this international consensus is to help nuclear medicine practitioners procedurally perform
18
F-flortaucipir PET imaging.
Method
A multidisciplinary task group formed by experts from various countries discussed and approved the consensus for
18
F-flortaucipir PET imaging in Alzheimer’s disease (AD), focusing on clinical scenarios, patient preparation, and administered activities, as well as image acquisition, processing, interpretation, and reporting.
Conclusion
This international consensus and practice guideline will help to promote the standardized use of
18
F-flortaucipir PET in patients with AD. It will become an international standard for this purpose in clinical practice.</description><subject>Alzheimer's disease</subject><subject>Cardiology</subject><subject>Cognitive ability</subject><subject>Fluorine isotopes</subject><subject>Guidelines</subject><subject>Image acquisition</subject><subject>Imaging</subject><subject>Medical imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neurodegenerative diseases</subject><subject>Neurology</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Orthopedics</subject><subject>Patients</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Radioactive tracers</subject><subject>Radiology</subject><subject>Tau protein</subject><subject>Tomography</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kcFqFTEUhoMotlZfwFXAjZvRk2QyyWyEUlotFHTRrkNu5mRuytzkmsxY6srX8PV8EnO9pdIuujoHzvf__JyfkLcMPjAA9bEAcNk3wFkDslOiuXlGDlnH-kaB7p_f7woOyKtSrgGY5rp_SQ5E2yste3lI8DzOmKOdQ4p2oi7FgrEshaZI5zXSpSBNns52od9OL2nY2DHEkdoR40yZPmv8lHK9urANmYZIj6efawwbzH9-_S50CAVtwdfkhbdTwTd384hcnZ1ennxpLr5-Pj85vmic0GxupODaM-W9whYH4RxHzlbQI28RAJ0WrtODBC-Z4u1g7apnrQOu3Uoid14ckU973-2y2uDgashsJ7PNNXe-NckG8_ASw9qM6YfRGoRSvBq8vzPI6fuCZTabUBxOk42YlmJ4xzquFcgd-u4Rep2W-slpR_EWRCtlWym-p1xOpWT092EYmF2LZt-iqS2afy2amyoSe1GpcBwx_7d-QvUXfyahDg</recordid><startdate>20220201</startdate><enddate>20220201</enddate><creator>Tian, Mei</creator><creator>Civelek, A. Cahid</creator><creator>Carrio, Ignasi</creator><creator>Watanabe, Yasuyoshi</creator><creator>Kang, Keon Wook</creator><creator>Murakami, Koji</creator><creator>Garibotto, Valentina</creator><creator>Prior, John O.</creator><creator>Barthel, Henryk</creator><creator>Zhou, Rui</creator><creator>Hou, Haifeng</creator><creator>Dou, Xiaofeng</creator><creator>Jin, Chentao</creator><creator>Zuo, Chuantao</creator><creator>Zhang, Hong</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220201</creationdate><title>International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease</title><author>Tian, Mei ; Civelek, A. Cahid ; Carrio, Ignasi ; Watanabe, Yasuyoshi ; Kang, Keon Wook ; Murakami, Koji ; Garibotto, Valentina ; Prior, John O. ; Barthel, Henryk ; Zhou, Rui ; Hou, Haifeng ; Dou, Xiaofeng ; Jin, Chentao ; Zuo, Chuantao ; Zhang, Hong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-5328f17ff7e4ed3cc2e21b09e24e00ec83c68d50f51724daab914c028cb5e2cf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Alzheimer's disease</topic><topic>Cardiology</topic><topic>Cognitive ability</topic><topic>Fluorine isotopes</topic><topic>Guidelines</topic><topic>Image acquisition</topic><topic>Imaging</topic><topic>Medical imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neurodegenerative diseases</topic><topic>Neurology</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Orthopedics</topic><topic>Patients</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Radioactive tracers</topic><topic>Radiology</topic><topic>Tau protein</topic><topic>Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tian, Mei</creatorcontrib><creatorcontrib>Civelek, A. Cahid</creatorcontrib><creatorcontrib>Carrio, Ignasi</creatorcontrib><creatorcontrib>Watanabe, Yasuyoshi</creatorcontrib><creatorcontrib>Kang, Keon Wook</creatorcontrib><creatorcontrib>Murakami, Koji</creatorcontrib><creatorcontrib>Garibotto, Valentina</creatorcontrib><creatorcontrib>Prior, John O.</creatorcontrib><creatorcontrib>Barthel, Henryk</creatorcontrib><creatorcontrib>Zhou, Rui</creatorcontrib><creatorcontrib>Hou, Haifeng</creatorcontrib><creatorcontrib>Dou, Xiaofeng</creatorcontrib><creatorcontrib>Jin, Chentao</creatorcontrib><creatorcontrib>Zuo, Chuantao</creatorcontrib><creatorcontrib>Zhang, Hong</creatorcontrib><creatorcontrib>Molecular Imaging-based Precision Medicine Task Group of A3 (China-Japan-Korea) Foresight Program</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tian, Mei</au><au>Civelek, A. Cahid</au><au>Carrio, Ignasi</au><au>Watanabe, Yasuyoshi</au><au>Kang, Keon Wook</au><au>Murakami, Koji</au><au>Garibotto, Valentina</au><au>Prior, John O.</au><au>Barthel, Henryk</au><au>Zhou, Rui</au><au>Hou, Haifeng</au><au>Dou, Xiaofeng</au><au>Jin, Chentao</au><au>Zuo, Chuantao</au><au>Zhang, Hong</au><aucorp>Molecular Imaging-based Precision Medicine Task Group of A3 (China-Japan-Korea) Foresight Program</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><date>2022-02-01</date><risdate>2022</risdate><volume>49</volume><issue>3</issue><spage>895</spage><epage>904</epage><pages>895-904</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Purpose
Positron emission tomography (PET) with the first and only tau targeting radiotracer of
18
F-flortaucipir approved by FDA has been increasingly used in depicting tau pathology deposition and distribution in patients with cognitive impairment. The goal of this international consensus is to help nuclear medicine practitioners procedurally perform
18
F-flortaucipir PET imaging.
Method
A multidisciplinary task group formed by experts from various countries discussed and approved the consensus for
18
F-flortaucipir PET imaging in Alzheimer’s disease (AD), focusing on clinical scenarios, patient preparation, and administered activities, as well as image acquisition, processing, interpretation, and reporting.
Conclusion
This international consensus and practice guideline will help to promote the standardized use of
18
F-flortaucipir PET in patients with AD. It will become an international standard for this purpose in clinical practice.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>34978595</pmid><doi>10.1007/s00259-021-05673-w</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2022-02, Vol.49 (3), p.895-904 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8803772 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Alzheimer's disease Cardiology Cognitive ability Fluorine isotopes Guidelines Image acquisition Imaging Medical imaging Medicine Medicine & Public Health Neurodegenerative diseases Neurology Nuclear Medicine Oncology Orthopedics Patients Positron emission Positron emission tomography Radioactive tracers Radiology Tau protein Tomography |
| title | International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T22%3A17%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=International%20consensus%20on%20the%20use%20of%20tau%20PET%20imaging%20agent%2018F-flortaucipir%20in%20Alzheimer%E2%80%99s%20disease&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Tian,%20Mei&rft.aucorp=Molecular%20Imaging-based%20Precision%20Medicine%20Task%20Group%20of%20A3%20(China-Japan-Korea)%20Foresight%20Program&rft.date=2022-02-01&rft.volume=49&rft.issue=3&rft.spage=895&rft.epage=904&rft.pages=895-904&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-021-05673-w&rft_dat=%3Cproquest_pubme%3E2624034554%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2624034554&rft_id=info:pmid/34978595&rfr_iscdi=true |